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Abstract
The population structure of Mycobacterium tuberculosis is typically clonal therefore genotypic lineages can be unequivocally
identified by characteristic markers such as mutations or genomic deletions. In addition, drug resistance is mainly mediated
by mutations. These issues make multiplexed detection of selected mutations potentially a very powerful tool to
characterise Mycobacterium tuberculosis. We used Multiplex Ligation-dependent Probe Amplification (MLPA) to screen for
dispersed mutations, which can be successfully applied to Mycobacterium tuberculosis as was previously shown. Here we
selected 47 discriminative and informative markers and designed MLPA probes accordingly to allow analysis with a liquid
bead array and robust reader (Luminex MAGPIX technology). To validate the bead-based MLPA, we screened a panel of 88
selected strains, previously characterised by other methods with the developed multiplex assay using automated positive
and negative calling. In total 3059 characteristics were screened and 3034 (99.2%) were consistent with previous molecular
characterizations, of which 2056 (67.2%) were directly supported by other molecular methods, and 978 (32.0%) were
consistent with but not directly supported by previous molecular characterizations. Results directly conflicting or
inconsistent with previous methods, were obtained for 25 (0.8%) of the characteristics tested. Here we report the validation
of the bead-based MLPA and demonstrate its potential to simultaneously identify a range of drug resistance markers,
discriminate the species within the Mycobacterium tuberculosis complex, determine the genetic lineage and detect and
identify the clinically most relevant non-tuberculous mycobacterial species. The detection of multiple genetic markers in
clinically derived Mycobacterium tuberculosis strains with a multiplex assay could reduce the number of TB-dedicated
screening methods needed for full characterization. Additionally, as a proportion of the markers screened are specific to
certain Mycobacterium tuberculosis lineages each profile can be checked for internal consistency. Strain characterization can
allow selection of appropriate treatment and thereby improve treatment outcome and patient management.
Citation: Bergval I, Sengstake S, Brankova N, Levterova V, Abadı´a E, et al. (2012) Combined Species Identification, Genotyping, and Drug Resistance Detection of
Mycobacterium tuberculosis Cultures by MLPA on a Bead-Based Array. PLoS ONE 7(8): e43240. doi:10.1371/journal.pone.0043240
Editor: Igor Mokrousov, St. Petersburg Pasteur Institute, Russian Federation
Received April 11, 2012; Accepted July 18, 2012; Published August 20, 2012
Copyright:  2012 Bergval et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by ZonMW project nr. 205100005. The funders had no role in the study design, data collection and analysis, decision to publish
or preparation of the manuscript.
Competing Interests: The authors have the following interests: K. Tuin is an employee of MRC-Holland the manufacturer of commercial MLPA assays. Luminex
BV provided technical assistance. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to
all the PLoS ONE policies on sharing data and materials.
* E-mail: r.anthony@kit.nl
. These authors contributed equally to this work.
¤a Current address: Research Institute of Tuberculosis and Lung Diseases, National Reference Laboratory, Baku, Azerbaijan
¤b Current address: Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands
Introduction
Effective treatment of patients infected with (drug-resistant) TB
relies on accurate diagnosis and appropriate therapy. It is
therefore crucial to confirm and characterise the species present
in sputum cultures [1] as well as to detect drug resistance at an
early stage. Unfortunately in many high burden settings culture of
sputum samples, if performed at all, is not followed by further
molecular characterisation [2]. This can lead to suboptimal
treatment and patient management.
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e43240
Over the last years a diverse range of molecular tools have been
developed to characterise and type Mycobacterium tuberculosis
complex. Only a proportion of these methods, based on
identification/detection of CRISPRs (spoligotyping), insertion
sequences (IS6110 Restriction Fragment Length Polymorphism
(RFLP)), large sequence polymorphisms (LSPs), Regions of
Difference (RD) typing or tandem repeats (Mycobacterial Inter-
spersed Repetitive Units-Variable Number of Tandem Repeats
(MIRU-VNTR) have been widely applied [3–7].
Genetic information derived by these typing methods from
tuberculosis (TB) strains all over the world has revealed the clonal
architecture, the phylogeography and evolutionary descent of
different strains [7–13]. The challenge with monomorphic
bacteria is that they contain so little sequence diversity that
sequencing a few gene fragments yields little or no information
thereby making it difficult to identify variable regions suitable for
epidemiological studies. However, for genotyping purposes this
clonal population structure is quite advantageous, as transfer of
DNA does not occur and the accumulated genetic changes are
fixed, which can be used to unequivocally identify specific lineages
[9,14]. Drug resistance mutations are observed in multiple lineages
because they arose under strong selective pressure whereas
mutations occurring through random genetic drift are fixed and
unique to specific lineages [9].
Drug resistance in M. tuberculosis isolates is largely due to a
limited diversity of mutations [15–19] and not the acquisition of
(plasmid-mediated) resistance genes. Detection of clustered drug
resistance mutations in M. tuberculosis by sequencing [20], reverse
hybridisation to low-density arrays [21,22] or molecular beacons
in a PCR reaction [23,24] has been extraordinarily successful.
These methods form the theoretical basis for almost all currently
used molecular methods for the detection of drug resistance in M.
tuberculosis. Unfortunately, although very effective, the methods
used to date do not naturally lend themselves to highly multiplexed
detection of dispersed markers and full genetic characterization of
M. tuberculosis isolates therefore requires multiple tests.
Traditionally the diagnosis, culture and typing of M. tuberculosis
relies on dedicated methods, requiring specially trained workers
and specially equipped laboratories. This situation persists because
of the slow growth and need for specialised media and laboratory
safety infrastructure. In areas where TB is less prevalent or where
TB is prevalent but resources are too limited to have dedicated
staff and laboratories, this can be a problem. One consequence is
that molecular typing and, to some extent, determination of drug
resistance are often performed retrospectively and generally only
routinely performed in supra-national centers.
In the last decade there has been an explosion of genome
sequences from large numbers of M. tuberculosis strains, revealing
the presence of many lineage-specific genetic markers, such as
unique SNPs and regions of difference (RDs), in addition to the
markers which are currently in use [6,8,10–13,25,26].
As outlined above, the population structure of M. tuberculosis is
clonal with no evidence of horizontal gene transfer. Markers (SNPs
or deletions) associated with resistance or specific for distinct
lineages can therefore be unequivocally identified and defined,
making multiplexed detection methods for characterization of M.
tuberculosis isolates very appealing.
Methods for multiplex SNP detection are available but have
only rarely been developed for typing bacterial pathogens [27–30].
Here we report a novel multiplexing assay, allowing the
simultaneous detection of an extensive panel of both drug
resistance and genotypic markers in M. tuberculosis isolates. We
used an established method of multiplex SNP typing which we
have previously shown to be suitable for use with M. tuberculosis, the
MLPA [28,31]. This method was adapted so results can be
analysed using a recently released liquid array reader based on a
flow cell and CCD imaging (MAGPIX, Luminex, Austin, USA).
We believe this technology offers a robust and potentially cost
effective platform appropriate for use in tuberculosis laboratories
performing culture.
The MAGPIX platform allows up to 50 analytes to be tested in
a single tube per sample. We thus designed MLPA probes to target
47 informative markers and three internal controls. Included
markers were selected based on the previous assay [28], published
literature, or in silico searches. Markers targeting drug resistance
associated mutations, mycobacterial species specific regions, M.
tuberculosis genotype specific markers, as well as markers identifying
epidemic strains, were included in the assay to demonstrate the
versatility of this approach for the characterization of M. tuberculosis
isolates. The method was validated using a panel of 88 selected
well-characterised strains derived from various regions of the
world, consisting of M. tuberculosis complex strains and non-
tuberculous mycobacteria.
Methods
MLPA assay
A schematic overview of the MLPA assay is shown in Figure 1.
In this study, the analysis of amplified MLPA probes was
performed using the Luminex xTAG technology on the MAGPIX
platform, a compact and robust device. Read-out is facilitated by a
unique xTAG (24 nt) present on each amplified MLPA probe,
which is complementary to the anti-xTAG on one bead in the
array. The MAGPIX unlike previous Luminex readers is based on
a CCD camera and LED illuminated flow cell rather than a flow
cytometer. All MLPA probes and reagents were manufactured and
supplied by MRC-Holland (Amsterdam, The Netherlands).
MLPA reaction. MLPA was performed according to the
One-Tube MLPA Protocol for DNA detection and Quantification
developed by MRC-Holland (www.mlpa.com) and as previously
described [28] except that in this study MLPA probes were
denatured for 10 minutes at 98uC before the overnight
hybridisation step and MLPA probes were amplified by PCR
(35 cycles of 30s at 95uC, 30s at 60uC and 45s at 72uC). MLPA
products were analysed using the bead-based Luminex xTAG/
MAGPIX system. MLPA probes were used in a concentration of 2
fmol of each probe per MLPA reaction. For amplification of
ligated probes 2 ml of primermix (3.2 mM or 6.4 mM Cy3-labelled
forward primer, 1.6 mM reverse primer, 4 mM dNTPs) was used
per reaction. All steps of the MLPA were performed in a single
tube for each sample using a single thermocycler program. Three
extra samples were included in every experiment to monitor the
quality of the assay: 1) a negative control (no DNA template or
MLPA probes) to detect contamination with amplified MLPA
products, 2) a contamination control to detect contamination with
DNA template containing all reagents and MLPA probes, and
DNA from a species other than MTBC and 3) a positive assay
control containing all reagents, MLPA probes and template DNA
from a previously characterised laboratory strain RB14 ([28] and
Table S1).
From all DNA samples, irrespective of the DNA extraction
procedure or concentration, 3 ml of template DNA was used for
the MLPA assay. Agarose gel electrophoresis was used for
confirmation of successful amplification but not for marker
discrimination since all amplicons are approximately the same
length.
Analysis of the MLPA products. The Luminex xTAG
technology combined with the MAGPIX platform allows multi-
Bead-Based M. tuberculosis-Specific MLPA
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Figure 1. Overview of the bead-based Multiplex Ligation-dependent Probe Amplification (MLPA) assay. (a) MLPA oligo design. MLPA
oligos were designed to test for (1) single nucleotide polymorphism, the absence (2) or presence (3) of a region of difference (RD), (4) species-specific
sequences (b) Hybridisation of MLPA oligos to target DNA. Sequence-specific sequences hybridise to target DNA (DNA1 and DNA2). Each probe
consists of a target-specific sequence (grey bars), a unique xTAG (orange bar), forward and reverse primer binding sequences (red and green bars).
The MLPA oligos perfectly match to the sequence of DNA1 that harbours a SNP but not to DNA2. (c) Ligation of hybridised oligos. Only oligos that are
hybridised directly adjacent to each other are ligated. (d) Amplification of ligated oligos by PCR. All ligated oligos are amplified in a PCR reaction
using a single Cy3-labelled forward primer and unlabelled reverse primer. (e) Hybridisation of MLPA products to beads. Amplified probes hybridise to
their anti-xTAG coupled to an individual bead species. (f) Analysis of bead-probe complexes on the MAGPIX. A red light emitting diode (LED) and a
CCD camera identify first the individual bead species before green LEDs excite the reporter molecules on the probes. The signal is translated into
Median Fluorescence Intensity (MFI). For DNA1 a reporter signal is detected on the bead species indicating the presence of the SNP, thus a mutation,
in the respective DNA.
doi:10.1371/journal.pone.0043240.g001
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plexed analysis of up to 50 targets in a single assay. In this study we
aimed to use the full multiplexing capacity of the MAGPIX and
designed probes for the analysis of 47 mycobacterial targets and
three controls.
The three controls included were: 1. The LumQ control is used
to monitor the quantity of template DNA. It consists of two
random oligos of 74 and 80 nt, both of which contain forward and
reverse primer sites and the same xTAG. The LumQ oligos do not
require ligation, they are ready to be amplified by PCR. However
they are present in a very low concentration compared to the
concentration of each MLPA oligo in a sample. If the MFI signal
from the LumQ bead is low (MFI signals #50), this indicates that
enough (target) DNA was present and the ligation reaction was
successful. If the LumQ signal is high (MFI signals $300), this
indicates that not enough (target) DNA was present or that the
ligation reaction failed. 2. The LumD control indicates efficient
denaturation and ligation (Table 1). Like the other MLPA probes
it consists of two oligos each with a primer site and one with a
unique xTAG. One of the LumD oligos targets a GC-rich
sequence of the recA gene present in all members of the MTBC.
This oligo has the highest GC content of all probes in the assay
(GC-content of 91%). If the mycobacterial DNA denaturation was
successful, a signal will be obtained from the LumD-specific beads.
Both the LumD and LumQ controls are added to the samples
along with the MLPA probes at a concentration of 2.4 fmoles/
sample and 36 zeptomoles/sample, respectively. 3. The LumH
control indicates adequate hybridisation of the MLPA products to
the beads. The LumH control does not require ligation or
amplification and consists of a single short Cy3-labelled oligo with
an xTAG sequence binding to a unique bead species (Table 1). An
amount of 1 pmoles of LumH control is added to each sample with
the bead mix directly prior to analysis on the MAGPIX device.
For the analysis of the amplified MLPA products using the
bead-based array, we used an adapted version of ‘Sample protocol
for direct DNA hybridisation –Washed Assay Format using magnetic
microspheres’ provided by Luminex. (http://www.luminexcorp.com/
prod/groups/public/documents/lmnxcorp/washed-direct-dna-
magnetic.pdf) last access 20-06-2012. We used Cy3-labelled
MLPA primers, eliminating the need for an additional hybrid-
isation step to the reporter dye streptavidin-phycoerythrin,
thereby reducing the hands-on time. Briefly, 10 ml of MLPA
product per sample was hybridised to 500 beads of each bead
species in a total volume of 50 ml (33 ml 1.5 x TMAC buffer (5M
TMAC, 20% Sarkosyl, 1M Tris-HCL pH 8.0, 0.5 M EDTA
pH 8.0, beads resuspended therein), 7 ml of Tris-EDTA (1 mM
EDTA, 10 mM Tris-HCl, pH 8.0) and 20 nM LumH control).
MLPA products were denatured in a thermocycler for 10 min at
95uC followed by hybridisation to the beads for 30 min at 45uC.
This mixture was directly analysed on the MAGPIX equipment
without additional washing. A minimum of 35 beads per species
were counted and analysed per sample. A beads-only control
(extra sample), was included each time the assay was run for
background signal analysis. Median fluorescence Intensity (MFI)
signals from the samples were measured on the MAGPIX
equipment using the xPonent 5.1 software (Luminex, Austin, TX,
USA).
Data analysis. Based on preliminary testing of DNA from
MTBC cultures a Median Fluorescence Intensity (MFI) value of
150 was selected as a threshold value for all markers. Automated
calls were set up for the identification of MDR-TB, XDR-TB, M.
tuberculosis lineages, sublineages and NTM on the basis of
algorithms and comprehensive MTBC phylogeny (Figure 2). Data
analysis was performed using a dedicated Excel spreadsheet
(Microsoft Seattle, USA). The csv-file produced by the xPonent
software was imported into the Excel worksheet. The profiles were
first checked for validity; inclusion criteria were a MFI signal for
MTBC 16S rRNA-specific beads equal to or higher than 150 or
an MFI signal from an NTM bead equal to or higher than 150.
Signals from other beads were then considered positive if the MFI
measured was equal to or greater than 150 and conditional
formatting was used to highlight this signal.
We thus obtained an MLPA profile from every analysed strain
which is reported in Figure 3 (black squares indicate the presence
of an MLPA product, white squares indicate the absence of an
MLPA product). The correlation of this profile with the previously
collected data was also assessed. MLPA results (positive or
negative) that were supported by previously collected data (Table
S1) are indicated with a green dot in Figure 3 along with any
results that directly contradict or conflict with previously collected
data (Figure 3, indicated with a red X). MLPA results that do not
conflict with previously available data but are not directly
confirmed by this data are regarded as unsupported and merely
reported as a black or white square in Figure 3.
Although T strains may be members of multiple sublineages
[32], they are always expected to be members of the MTB4
lineage. Therefore the assignment of a strain to MTB4, as
classified by MLPA by presence of pks-15/1, is considered to be
supported if previously determined T family by spoligotyping.
Any strain assigned to one of the Beijing lineages by MLPA
could only be confirmed for strains where sequencing data was
available; only sequencing has the ability to assign a strain to the
Beijing lineages K1, V2, V+, SA2, SA+, CHIN2, CHIN+
[33,34]. In this study, a strain is identified as Beijing if the RD105
region is deleted and at least one other Beijing marker is present
[35]. If a strain was identified as Beijing by both MLPA and
spoligotyping we considered the Beijing marker RD105 con-
firmed. If genotypic information was available from two methods,
sequencing was chosen over spoligotyping and spoligotyping over
MIRU-VNTR to be compared to the MLPA results obtained.
Selection of strains/DNA targets
The MLPA assay was evaluated using 79 selected M. tuberculosis
complex strains, nine non-tuberculous mycobacterial (NTM)
strains and one other unrelated bacterial species (Table S1). This
panel of tested strains consisted of cultured clinical isolates and
previously described laboratory-generated mutants [28]; they were
selected so that the wildtype and the mutant form of all targeted
loci (Table 1) were represented at least once. Strains 1–4, 6–57,
62–69, 74, 80–87 were provided by the Tuberculosis Reference
Laboratory of the National Institute for Public Health and the
Environment, Bilthoven, The Netherlands. Strains 58–61 were
provided by the National Center of Infectious and Parasitic
Diseases, Sofia, Bulgaria. All Bulgarian strains were identified as
MDR-TB on the basis of drug susceptibility testing (BACTEC
MGIT 960, BD Sparks, MD, USA) and/or reverse hybridisation
assays (MTBDRplus and MTBDRsl, Hain Lifescience GmbH,
DE). Strains 70–73 were provided by the National Reference
Center for Tuberculosis, Tbilisi, Georgia. Strains 5, 75–79, 88–89
were from KIT Biomedical Research, Royal Tropical Institute,
Amsterdam, The Netherlands. A summary of the selected strains
and strain-specific information available is shown in Table S1.
DNA isolation. DNA from bacterial cultures grown from
single colonies was obtained by thermolysis [28], cetyltrimethy-
lammonium bromide (CTAB) procedure [36] or column-based
purification (QIAGEN Benelux B.V., Venlo, The Netherlands).
Sequencing of targeted loci. In some cases insufficient
background information on the strain was available and DNA
sequences targeted by MLPA probes were sequenced in selected
Bead-Based M. tuberculosis-Specific MLPA
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e43240
T
a
b
le
1
.
Su
m
m
ar
y
o
f
th
e
M
LP
A
p
ro
b
e
s
d
e
si
g
n
e
d
an
d
u
se
d
in
th
is
st
u
d
ya
.
P
ro
b
e
s
T
a
rg
e
t
T
a
rg
e
t-
sp
e
ci
fi
c
se
q
u
e
n
ce
(5
9–
3
9)
T
a
rg
e
t
o
r
in
fo
rm
a
ti
o
n
p
ro
v
id
e
d
[r
e
f]
e
m
b
B
-3
0
6
w
t
[2
8
]
EM
B
re
si
st
an
ce
m
ar
ke
r
ka
tG
-3
1
5
m
u
t
(A
G
C
3
1
5
A
C
C
)
[2
8
]
IN
H
re
si
st
an
ce
m
ar
ke
r
in
h
A
-1
5
m
u
t
(2
1
5
C
/T
)
[2
8
]
IN
H
re
si
st
an
ce
m
ar
ke
r
rp
o
B
-1
7
6
m
u
t
(G
T
C
1
7
6
T
T
C
)
[2
8
]
R
IF
re
si
st
an
ce
m
ar
ke
r
rp
o
B
-5
2
2
m
u
t
(T
C
G
5
2
2
T
T
G
)
[2
8
]
R
IF
re
si
st
an
ce
m
ar
ke
r
rp
o
B
-5
2
6
G
m
u
t
(C
A
C
5
2
6
G
A
C
)
[2
8
]
R
IF
re
si
st
an
ce
m
ar
ke
r
rp
o
B
-5
2
6
T
m
u
t
(C
A
C
5
2
6
T
A
C
)
[2
8
]
R
IF
re
si
st
an
ce
m
ar
ke
r
rp
o
B
-5
3
1
m
u
t
(T
C
G
5
3
1
T
T
G
)
[2
8
]
R
IF
re
si
st
an
ce
m
ar
ke
r
g
yr
A
-9
0
m
u
t
(G
C
G
9
0
G
T
G
)
G
C
A
C
C
A
G
G
C
T
G
T
C
G
T
A
G
A
T
C
G
A
C
A
FL
Q
re
si
st
an
ce
m
ar
ke
r
[7
4
]
C
G
TC
G
C
C
G
TG
C
G
G
G
TG
G
TA
G
TT
G
C
C
C
A
TG
G
TC
TC
G
g
yr
A
-9
4
m
u
t
(G
A
C
9
4
G
G
C
)
C
A
C
G
G
C
G
A
C
G
C
G
T
C
G
A
T
C
T
A
C
G
G
FL
Q
re
si
st
an
ce
m
ar
ke
r
[5
3
]
C
A
G
C
C
TG
G
TG
C
G
C
A
TG
G
C
C
C
A
G
C
C
C
TG
G
T
rr
s-
1
4
0
1
w
t
C
G
G
G
C
C
T
T
G
T
A
C
A
C
A
C
C
G
C
C
C
G
T
C
A
A
M
K
/K
A
N
/C
A
P
re
si
st
an
ce
m
ar
ke
r
[5
1
,5
2
]
C
G
TC
A
TG
A
A
A
G
TC
G
G
TA
A
C
A
C
C
C
G
A
A
G
C
C
A
G
TG
G
C
C
-
TA
A
C
C
C
TC
G
G
G
A
G
G
rr
s-
1
4
0
2
m
u
t
(1
4
0
2
C
/T
)
C
T
T
C
G
G
G
T
G
T
T
A
C
C
G
A
C
T
T
T
C
A
T
G
A
C
A
C
A
P
re
si
st
an
ce
m
ar
ke
r
[5
1
,5
3
]
TG
A
C
G
G
G
C
G
G
TG
TG
TA
C
A
A
G
G
C
C
C
G
G
G
A
A
C
G
TA
TT
C
A
C
C
G
C
A
G
C
G
rp
sl
-4
3
w
t
C
C
C
G
C
G
T
G
T
A
C
A
C
C
A
C
C
A
C
T
C
C
G
A
A
S
re
si
st
an
ce
m
ar
ke
r
[7
5
]
G
A
A
G
C
C
G
A
A
C
TC
G
G
C
G
C
TT
C
G
G
A
A
G
G
TT
G
C
C
C
G
C
G
M
T
B
C
1
6
S
rR
N
A
M
T
B
C
-s
p
e
ci
fc
se
q
u
e
n
ce
[2
8
]
1
6
S
rR
N
A
g
e
n
e
,
M
.
tu
b
er
cu
lo
si
s
co
m
p
le
x
sp
e
ci
fi
c
m
u
tT
2
-5
8
m
u
t
(G
G
A
5
8
C
G
A
)
[2
8
]
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
B
e
iji
n
g
K
1
,
V
+,
SA
+
[3
3
,3
4
]
ah
p
C
-4
6
m
u
t
(2
4
6
A
/G
)
C
G
G
C
G
A
T
G
C
C
G
A
T
A
A
A
T
A
T
G
G
T
G
T
A
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
C
e
n
tr
al
A
si
an
[4
5
]
A
TA
TA
TC
A
C
C
TT
TG
C
C
TG
A
C
A
G
C
G
A
C
TT
C
A
C
G
G
C
o
g
t-
1
5
m
u
t
(A
G
C
1
5
A
C
C
)
[2
8
]
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
H
aa
rl
e
m
A
g
8
5
C
-1
0
3
m
u
t
(G
A
G
1
0
3
G
A
A
)
G
A
C
A
T
C
A
A
C
A
C
C
C
C
G
G
C
C
T
T
C
G
A
A
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
LA
M
[6
5
]
G
A
G
TA
C
TA
C
C
A
G
TC
A
G
G
G
TT
G
TC
G
G
TG
A
TC
A
TG
C
R
D
9
ta
rg
e
ti
n
g
th
e
ab
se
n
ce
o
f
th
e
R
D
C
C
G
C
C
G
A
A
A
A
T
T
A
C
T
A
C
C
G
G
A
G
C
A
G
e
n
o
ty
p
e
m
ak
e
r,
R
D
p
re
se
n
t
in
an
im
al
st
ra
in
s
an
d
M
.
a
fr
ic
a
n
u
m
-
W
e
st
-A
fr
ic
an
1
/2
[6
,2
6
]
G
C
G
C
C
C
G
TG
TC
G
TC
C
A
C
G
G
C
TG
C
G
A
TT
A
TT
G
C
C
T
re
cC
-1
4
9
1
m
u
t
(1
4
9
1
C
/G
)
C
C
G
T
C
G
T
G
C
A
C
A
A
C
A
C
G
T
G
G
C
G
G
T
T
G
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
X
fa
m
ily
[6
6
]
G
G
A
C
TC
G
A
C
C
G
C
A
TC
C
TC
A
C
C
G
G
G
G
TG
G
C
C
A
T
G
TC
fb
p
B
-2
3
8
m
u
t
(C
C
C
2
3
8
C
C
A
)
C
C
G
G
G
T
G
T
T
G
T
T
T
G
C
G
A
C
C
A
G
C
T
T
T
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
B
e
iji
n
g
K
1
,
V
+,
V
2
,
SA
+
[3
3
,3
4
,7
6
]
G
G
G
A
TC
TG
C
TG
C
G
TA
G
G
G
TC
G
TT
G
C
G
C
TC
C
C
A
TG
C
C
G
G
R
D
7
0
2
ta
rg
e
ti
n
g
th
e
ab
se
n
ce
o
f
th
e
R
D
G
A
G
C
T
C
G
A
C
C
C
G
C
T
C
G
A
A
T
C
C
C
A
G
C
A
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
M
.
a
fr
ic
a
n
u
m
W
e
st
-A
fr
ic
an
2
[7
7
,7
8
]
C
C
G
C
A
A
C
C
G
C
G
A
TT
C
G
C
C
G
G
G
A
G
C
TG
C
G
A
TC
A
TA
TA
C
A
G
C
TG
R
D
1
0
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
T
T
A
C
C
C
C
G
C
C
A
C
C
G
A
C
G
T
T
C
A
T
G
A
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
M
.
m
ic
ro
ti
,
M
.
b
o
vi
s,
M
.
p
in
n
ip
ed
ii,
M
.
a
fr
ic
a
n
u
m
W
es
t-
A
fr
ic
a
n
u
m
2
Bead-Based M. tuberculosis-Specific MLPA
PLOS ONE | www.plosone.org 5 August 2012 | Volume 7 | Issue 8 | e43240
T
a
b
le
1
.
C
o
n
t.
P
ro
b
e
s
T
a
rg
e
t
T
a
rg
e
t-
sp
e
ci
fi
c
se
q
u
e
n
ce
(5
9–
3
9)
T
a
rg
e
t
o
r
in
fo
rm
a
ti
o
n
p
ro
v
id
e
d
[r
e
f]
TC
G
G
A
TA
A
A
G
A
A
G
C
C
G
TT
G
TC
C
A
A
G
C
C
C
TC
G
G
G
A
C
G
G
C
C
G
C
C
G
[6
,7
8
]
ac
s-
1
5
5
1
m
u
t
(1
5
5
1
G
/A
)
C
G
C
T
C
G
C
A
T
A
G
A
C
C
C
C
G
A
C
G
G
C
G
C
A
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
B
e
iji
n
g
SA
+
[3
3
,3
4
]
A
TC
TG
G
G
TA
C
TA
G
G
C
C
G
C
A
TC
G
A
C
G
A
C
G
TG
A
TG
A
A
C
G
TG
TC
C
G
G
G
R
D
1
3
1
ta
rg
e
ti
n
g
th
e
ab
se
n
ce
o
f
th
e
R
D
G
A
A
C
G
C
C
A
T
G
A
T
T
T
C
C
T
G
G
T
C
G
G
A
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
B
e
iji
n
g
K
1
[6
4
]
A
G
C
C
G
G
TC
G
C
C
G
TC
G
A
G
C
T
C
G
G
C
TG
C
C
A
G
C
A
G
TG
C
R
D
1
-B
C
G
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
A
C
G
T
C
G
T
G
C
T
T
C
T
G
G
T
C
G
A
C
G
A
T
T
G
G
C
A
C
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
M
.
b
o
vi
s
B
C
G
[7
9
]
TC
C
A
G
C
C
G
C
C
C
G
G
A
TC
C
A
G
C
A
TC
TG
TC
TG
G
C
A
TA
G
C
TG
C
C
T
b
D
1
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
[2
8
]
G
e
n
o
ty
p
e
m
ar
ke
r,
p
re
se
n
t
in
"a
n
ce
st
ra
l"
T
B
al
kA
-2
6
0
m
u
t
(C
T
G
2
6
0
C
T
A
)
C
C
T
G
C
T
T
G
T
G
C
T
C
G
A
T
G
A
T
T
T
C
C
G
C
G
A
C
C
T
A
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
M
.
b
o
vi
s
[6
6
]
A
TG
A
C
G
G
C
C
A
C
TG
C
A
C
G
TT
G
C
C
G
A
C
G
G
C
TG
C
TG
R
D
1
2
ca
n
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
C
C
G
C
T
A
T
G
C
C
A
C
C
C
G
T
T
A
G
G
G
C
T
C
G
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
M
.
ca
n
et
ti
[6
,8
0
]
C
G
C
C
C
G
TG
C
G
C
C
A
TT
C
G
T
G
G
C
G
A
C
A
A
C
TG
C
R
D
1
-m
ic
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
C
T
G
T
T
C
A
A
A
C
A
A
A
T
C
A
G
C
G
A
C
A
A
A
A
T
G
G
G
A
C
T
C
G
G
C
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
M
.
m
ic
ro
ti
[7
9
]
G
C
A
G
C
G
C
G
C
G
C
TC
A
G
C
G
A
C
G
C
C
G
A
C
TG
G
C
A
T
ES
A
T
-6
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
ES
A
T
-6
C
T
G
G
G
G
C
G
G
T
A
G
C
G
G
T
T
C
G
G
A
G
G
C
G
G
e
n
o
ty
p
e
m
ar
ke
r,
ta
rg
e
t
se
q
u
e
n
ce
n
o
t
p
re
se
n
t
in
M
.
m
ic
ro
ti
,
M
.
b
o
vi
s
(B
C
G
)
[7
9
]
TA
C
C
A
G
G
G
TG
TC
C
A
G
C
A
A
A
A
A
TG
G
G
A
C
G
C
C
A
C
G
G
C
TA
C
C
G
A
G
C
TG
R
D
2
se
al
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
G
A
A
C
A
T
C
C
G
C
G
A
G
C
A
G
G
C
G
A
T
C
G
C
C
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
M
.
p
in
n
ip
ed
ii
[8
1
]
C
G
A
G
A
TG
C
C
G
A
TC
C
G
G
C
G
C
C
C
A
A
A
TG
C
G
G
C
R
D
1
0
5
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
G
G
C
G
T
G
C
C
G
T
C
G
C
G
C
C
C
G
T
C
C
C
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
al
l
B
e
iji
n
g
an
d
Ea
st
A
si
a
"N
o
n
-B
e
iji
n
g
b
lu
e
"
C
G
G
C
G
A
C
C
A
C
G
G
C
G
TC
C
A
C
C
G
G
G
TC
C
A
C
[2
5
,3
5
]
R
D
2
3
9
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
T
G
T
A
A
T
A
A
T
G
A
C
C
G
A
C
G
G
C
C
G
C
A
T
G
C
T
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
Ea
st
A
fr
ic
an
In
d
ia
n
[2
5
]
C
C
G
TT
G
C
TT
G
TC
G
TG
A
A
C
G
G
TT
TG
A
C
G
G
TG
A
TC
C
G
p
ks
1
5
/1
–
7
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
7
b
p
R
D
G
G
T
T
G
A
G
G
C
G
A
G
C
G
A
A
A
G
C
A
C
C
G
G
G
G
e
n
o
ty
p
e
m
ar
ke
r,
p
re
se
n
t
in
"m
o
d
e
rn
"
T
B
[8
1
]
G
G
C
C
G
C
G
G
C
C
G
TC
G
A
T
G
G
TG
C
C
G
TG
R
D
7
5
0
ta
rg
e
ti
n
g
th
e
p
re
se
n
ce
o
f
th
e
R
D
G
T
G
G
T
T
G
C
C
T
C
G
C
A
T
G
C
G
A
C
G
G
A
G
T
G
C
A
G
e
n
o
ty
p
e
m
ar
ke
r,
R
D
p
re
se
n
t
in
C
e
n
tr
al
A
si
an
[2
6
]
TT
G
G
TA
C
TT
G
C
A
TG
TG
C
G
G
C
A
TG
C
G
G
TG
G
G
C
G
p
ck
A
-1
1
1
9
m
u
t
(1
1
1
9
C
/T
)
G
C
A
T
T
G
G
T
T
T
C
C
G
T
C
T
C
G
C
G
G
A
A
G
T
A
C
C
A
A
G
e
n
o
ty
p
e
m
ar
ke
r,
sp
e
ci
fi
c
fo
r
B
e
iji
n
g
SA
-,
C
H
IN
-
[3
3
,3
4
]
TC
G
TT
G
C
C
C
TT
C
C
A
G
TC
G
A
TC
A
G
G
TG
C
TG
C
G
G
G
TC
G
N
T
M
1
6
S
rR
N
A
N
T
M
-s
p
e
ci
fi
c
se
q
u
e
n
ce
G
A
A
T
A
G
G
A
C
C
A
C
G
C
G
C
T
T
C
A
T
G
iii
T
G
T
G
G
T
G
G
A
A
A
G
C
1
6
S
rR
N
A
g
e
n
e
,
sp
e
ci
fi
c
fo
r
n
o
n
-t
u
b
e
rc
u
lo
u
s
m
yc
o
b
ac
te
ri
a
TT
TT
G
C
G
G
TG
TG
G
G
A
TG
G
G
C
C
C
G
C
G
G
C
C
TA
TC
A
G
C
TT
N
T
M
k
a
n
s
sp
e
ci
e
s-
sp
e
ci
fi
c
se
q
u
e
n
ce
G
C
G
A
G
C
A
T
C
A
A
A
T
G
G
A
T
G
C
G
T
T
G
C
C
C
T
A
ta
rg
e
t
sp
e
ci
fi
c
fo
r
M
.
ka
n
sa
si
i
(G
e
n
B
an
k
ID
:
A
B
0
2
6
6
9
5
.1
)
C
G
G
G
TA
G
C
G
TG
TT
C
TT
TT
G
TG
C
A
A
TT
TT
A
TT
C
TT
TG
G
TT
TT
TG
TG
N
T
M
x
e
n
sp
e
ci
e
s-
sp
e
ci
fi
c
se
q
u
e
n
ce
C
A
C
T
G
T
T
G
G
G
T
T
T
T
G
A
G
G
C
A
A
C
A
C
C
C
G
T
G
G
T
-
G
G
T
G
T
T
G
T
G
C
T
C
C
G
C
G
ta
rg
e
t
sp
e
ci
fi
c
fo
r
M
.
xe
n
o
p
i
(G
e
n
B
an
k
ID
:
Y
1
4
1
9
0
.1
)
TG
G
TG
G
C
G
G
G
G
TG
TG
G
TG
TT
TG
A
G
TG
TT
G
G
Bead-Based M. tuberculosis-Specific MLPA
PLOS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e43240
strains from the collection to resolve contradictory results (Table
S1 and Figure 3). The following primers were used to amplify and
sequence selected regions targeted by the MLPA probes: gyrA-
Forward (FW), 59- ACTATGCGATGAGCGTGATCG-39 and
gyrA-Reverse (RV), 59-ATGAAATCGACTGTCTCCTCGT-
CG-39 (gyrA codon 90, 94); rrs-FW, 59-ATCGCAGATCAG-
CAACGCTGC-39 and rrs-RV, 59- ACGGCTACCTTGTTAC-
GACTTCG-39, (rrs nucleotide positions 1401/1402); embB-FW,
59- ATCGAGGTCACCTCTACCCACG-39 and embB-RV, 59-
ATCCACAGACTGGCGTCGCTG-39, (embB codon 306); rpsl-
FW, 59- ATGCCAACCATCCAGCAGCTGG-39 and rpsl-RV,
59- AGACCGGGTCGTTGACCAACG-39, (rpsl codon 43);
Ag85C-FW, 59- ACATCAAGGTCCAGTTCCAG-39 and
Ag85C-RV, 59-AGGTGTAGTTCTGGCCGTTGC-39, (Ag85C
codon 103). The primers used to amplify the targeted regions in
rpoB, katG and inhA are described elsewhere [28].The following
primers were used to amplify and sequence the pncA and RD105
region: pncA-FW, 59- ATCCCAGTCTGGACACGTCG-39 and
pncA-RV, 59- AGGAGCTGCAAACCAACTCG-39. RD105-
FW, 59-AGTTCGATCACGGTGTCGGTG-39 and iRD105-
RV, 59-AGCACGCCTTGATATCAGCG-39;
iRD105-FW, 59-AGGCAAATGTTCGACGGATACC-39 and
RD105-RV, 59-ATCGCGAATCGTGGTGATCC-39. Sequenc-
ing of PCR products was performed using capillary sequencing on
an ABI 3730xl DNA analyzer by Macrogen Inc. (Amsterdam, The
Netherlands).
Genetic characterization of strains used. Identification of
drug resistance associated mutations was performed by reverse
hybridisation assays [37,38] or sequencing with primers listed in
the paragraph above. Genotypic information of included strains
was obtained by spoligotyping, MIRU-VNTR, IS6110-RFLP,
sequencing, or whole genome sequencing [4,32–34,39,40].
Selection of genetic markers and design of probes
Forty-seven discriminatory markers were selected to demon-
strate the potential of the MLPA assay. The markers were selected
on the basis of published information and are described below.
The sequence of these genetic markers was used by MRC-Holland
to design probes detecting the selected markers (Table 1). The
selected MLPA probes target single nucleotide polymorphisms
(SNPs), wildtype sequences, RDs, small deletions or species-
specific sequences. The MLPA assay was developed in stages with
an initial set of 27 probes before the final set of 47 probes and one
probe to control the assay was synthesised and tested.
Drug resistance markers. Markers associated with resis-
tance to the first line drugs rifampicin, isoniazid, ethambutol and
streptomycin, targeted by probes rpoB-176, rpoB-516, rpoB-522,
rpoB-526G, rpoB-526T, rpoB-531, inhA-15, katG-315, embB-
306, rpsl–43 and rpsl-88, respectively and markers identifying
molecular resistance to the second line drugs fluoroquinolones,
aminoglycosides and capreomycin targeted by probes, gyrA-90,
gyrA-94, rrs-1401, rrs-1402, respectively were chosen on the basis
of their reported in vivo prevalence and the importance of the drug
to which they confer resistance (Table 1). All probes target the
mutation conferring resistance except the probes embB-306, rpsl-
43 and rrs-1401. The decision of targeting the wildtype sequence
in the emB306 codon was based on the wide variety of resistance-
conferring basepair changes reported [28]. Wildtype sequences
were also targeted for the rpsl-43 and rrs-1401 loci because
targeting the mutant sequence was expected to result in
suboptimal specificity.
Genotyping markers. Markers for species identification
were selected to discriminate between a broad range of lineages
and sublineages of M. tuberculosis. We used data from a recently
T
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published and comprehensive phylogeny of MTBC strains [25,26]
and included additional genotypic markers validated in a
previously published MLPA assay [28] or published elsewhere
(Table 1).
These markers were selected to allow discrimination within
lineages and sublineages of MTBC strains (M. tuberculosis, M.
africanum West-African 1 and M. africanum West-African 2, M. bovis, M.
bovis BCG, M. canetti, M. pinnipedii, M. microti), as well as
identification of East African Indian (EAI), Central Asian (CAS),
East Asian (EA) ‘‘Non-Beijing blue’’, Beijing (Beijing SA+, SA2,
CHIN+, CHIN2, V+, V2, K1), M. tuberculosis 4 (MTB4: X
family, Haarlem and Latin-American/Mediterranean (LAM)
[25,26]. A lineage-specific deletion of 8bp in the pncA gene (nt
109–116) was targeted to identify a suspected dominant MTBC
strain allegedly circulating in Bulgaria.
MLPA probes targeting RDs either hybridise to a sequence
within the RD to detect an intact RD, or hybridise to the flanking
regions of an RD indicating the RD is deleted (Table 1).
Species identification of non-tuberculous
mycobacteria. Probes to detect the presence of a range of
NTMs were included (M. kansasii, M. xenopi, M. avium complex, M.
avium subsp. avium and M. fortuitum). These NTMs are identified by
probes targeting a species-specific sequence within the 16S-23S
rRNA intergenic spacer region. For identification of the non-
tuberculous mycobacteria M. xenopi, M. avium subsp. avium and M.
fortuitum, MLPA probes were designed containing three oligonu-
cleotides: the left probe oligo, the right probe oligo and a
sequence-specific spanning oligo in between. The introduction of a
second ligation site serves as an additional discrimination point
ensuring the specificity of these MLPA probes, as a standard
MLPA probe (composed of two oligonucleotides) would not be
sufficiently specific.
A more general probe targeting the presence of a small deletion
in the 16S rRNA in MTBC [41] but absent in many NTM species
was also included. An overview of the markers included and an
algorithm for the identification of lineages and sublineages is
shown in Table 1 and Figure 2.
Results
From an initial list of 85 markers, 47 markers were selected for
inclusion in the MLPA assay. These markers target diverse
Figure 2. Algorithm applied to all strains analysed for species identification of M. tuberculosis complex and non-tuberculous
mycobacteria. MLPA markers are framed and final NTM species, MTBC lineages or sublineages are shown in bold. The species identification of a
sample always starts with the MTBC 16SrRNA marker. As an example the call for the Beijing lineage K1 is highlighted with bold arrows. The following
markers are present or absent in a strain belonging to the Beijing K1 lineage: MTBC 16S rRNA (present), TbD1 (present), RD750 (absent), pks15/1–7
(absent), RD105 (present), fbpB-238 (present), muT2-58 (present), acs-1551 (absent), RD131 (present). * as defined in [25].
doi:10.1371/journal.pone.0043240.g002
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characteristics and enable discrimination within MTBC, identifi-
cation of NTM species and detection of molecular resistance to
anti-tuberculosis drugs. To streamline the process, probes were
designed and synthesised in two rounds. We performed initial
experiments to validate the first 30 MLPA probes. On the basis of
the strains tested we observed that recC-1491, RD702 and RD207
were producing false-positive results or were non-functional. The
recC-1491 and RD702 probes were redesigned and the RD207
Figure 3. Validation of MLPA probes on 88 previously characterised mycobacterial strains. The MLPA was performed on 79 M.
tuberculosis isolates (strains 1–79), nine non-tuberculosis mycobacteria (strains 80–88) and one species unrelated to mycobacteria (strain 89). Species
identification was determined on the basis of the presence or absence of MLPA markers following calls mentioned in Figure 2. Results obtained by
MLPA were compared to results obtained from testing the same strain by other molecular methods. aStrain-specific drug resistance profiles and
genotypic information obtained by other molecular methods is available in Table S1. The presence or absence of an MLPA product is indicated with a
black square or a white square, respectively. The confirmation of the MLPA result by other molecular methods is indicated with a green dot;
conflicting results between MLPA and other molecular methods are indicated with a red cross. ND= Analysis for this marker was not done. MTB4 is
defined as M. tuberculosis group 4 [26] but not X family, LAM or Haarlem.
doi:10.1371/journal.pone.0043240.g003
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probe was replaced with pckA-1119. These probes were tested
along with 17 additional MLPA probes (47 probes in total) on
different strains. Of the 47 MLPA probes, four probes produced
false-positive results or were non-functional (RD711, pncA, rpoB-
516 and rpsl-88). Thus for the strains analysed we have data from
23 or 43 MLPA probes available. MLPA products were always
analysed using the 50 unique-coded beads of which 47 bead
species provided information about drug resistance, species,
lineage and strain identification and three bead species were
reserved to monitor the quality of the assay.
Of the 47 probes, four probes were recognised as nonfunctional
and excluded from the study. The 43 remaining probes are
described in detail in Table 1.
The four nonfunctional probes target rpoB-D516V (rifampicin
resistance), rpsl-K88R (streptomycin resistance), pncA (genotypic
marker) and RD711 (genotypic marker). The markers rpoB-516
and rpsl-88 gave non-specific false positive results and pncA and
RD711 probes were nonfunctional (Figure 4).
During validation, DNA from 89 bacterial strains was analysed
by MLPA to establish the performance of 43 genotypic and drug
resistance markers and the LumD and LumH control. All DNA
extraction methods tested (thermolysis, CTAB method or column
purification) produced interpretable results. Of the 43 functional
MLPA probes, 30 were designated for species, lineage and strain
identification and 13 targeted resistance associated genetic
markers. Results obtained by MLPA for all 89 analysed strains
were first checked for consistency and then compared to genotypic
information available from sequencing, spoligotyping, line probe
assays, MIRU-VNTR, IS6110-RFLP, or genetic characterization
of resistance markers (Table S1, Figure 2). In total 3059
characteristics were screened of which 1915 were informative for
species identification and 1144 were informative for molecular
resistance to first and second line drugs (Figure 3).
Based on our initial experience with the assay we set an MFI
threshold value of 150 for the presence or absence of a marker,
although in principle a threshold could be independently
established for each probe.
Controls
Of the three internal controls LumQ, LumD, LumH, initially
only LumD and LumH were functional and therefore used in the
assay. For both controls, LumH and LumD, we obtained MFI
signals higher than 300. The LumD control detected MTBC DNA
and confirmed it was adequately denatured (Table S2); a positive
signal with the LumH control was obtained independently of the
DNA sample tested (data not shown). The LumQ control was
subsequently shown to be functional when the oligo was present in
Figure 4. Dot plot of MLPA probe-specific MFI values of strains analysed. Median fluorescence intensity (MFI) values are indicated for each
MLPA probe for every mycobacterial strain tested. The threshold used to call the presence or absence of a maker, MFI of 150, is indicated with a
horizontal dashed line. Non-functional MLPA probes are indicated to the right side of the plot separated with a vertical dashed line. False positives or
false negatives are highlighted in red. Brackets indicate whether a MLPA probe targets the wildtype sequence (wt), SNP (mut), the presence (P) or
absence (A) of an RD, or a species-specific sequence (S).
doi:10.1371/journal.pone.0043240.g004
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the probemix at a four times higher concentration than previously
used (4 times 12x10221 moles) (data not shown).
The specificity of the assay was also tested on DNA from S.
aureus. We never observed an MFI higher than the set threshold for
the 16SrRNA MTBC marker, but occasionally an MFI value
higher than 150 was obtained for some of the other markers.
Internal consistency check of the MLPA markers
All 88 mycobacterial strains were checked for the consistency of
MLPA markers present or absent based on the decision tree
(Figure 2). In 19 strains (strain 43–46, 49, 51–52, 54–58, 60–61,
68–69, 71–72, 77) markers specific for two distinct of two lineages
were found thereby causing an inconsistent call (Figure 3), this
data is summarised in Table S3. The presence of the markers
pks15/1–7 or acs together with a marker of another TB lineage
caused an inconsistent call for these strains. These strains could
therefore not be assigned to one of the lineages. For five strains (44,
54, 58, 60–61) the presence of the genotypic marker RD131 or acs
alone caused an inconsistent call since these markers characterise a
Beijing sublineage only together with the presence of other
markers (fbpB-238 and mutT2-58).
All screened mycobacteria other than tuberculosis, M. kansasii,
M. xenopi and M. avium subsp. avium, M. avium complex and M.
fortuitum, were detected and the probes used to detect these species
did not give a signal for any of the MTBC isolates tested (Figure 3).
The NTM 16S rRNA marker was detected in M. kansasii, M. avium
complex and M. fortuitum (Figure 3).
Comparison of MLPA results to other molecular typing
methods
Of 1915 characteristics screened for genotype identification,
1862 (97.2%) of them were supported by other molecular
methods, 29 (1.5%) were consistent but not supported by other
molecular methods and 24 (1.3%) showed discordant results when
compared to other molecular methods (Figure 3).
Strain 21 was previously defined as East Asia ‘‘Non-Beijing
blue’’ based on the presence of RD105 [25]. However, the
presence of RD105 could not be confirmed by MLPA (Figure 3).
This finding was confirmed by PCR-amplification of the RD105
region in strain 21. Primers could amplify the flanking regions of
RD105. Based on the markers screened for strain 21 could not be
assigned to any of the MTBC lineages. Spoligotyping of this strain
resulted in a spoligotype pattern that also could not be designated
to one of the major lineages.
Based on whole genome sequencing, strain 50 was assigned to
the Beijing lineage V+/CHIN+. In addition to the markers
defining the Beijing lineage V+/CHIN+ (RD105, fbpB-238 and
mutT2-58), MLPA also detected a mutation in acs-1551. This
strain was thus assigned to the Beijing lineage SA+ thereby causing
a conflicting assignment within the Beijing lineage between MLPA
and sequencing.
In the 19 strains (strain 43–46, 49, 51–52, 54–58, 60–61, 68–69,
71–72, 77) that could not be assigned to a single lineage, the
presence of pks15/1–7, acs and RD131 markers in these strains
detected by MLPA could not be confirmed by other molecular
methods. MFI values around the set MFI threshold of 150
appeared to be the cause of these potentially false positive results
(Figure 4).
The absence of the NTM 16S rRNA marker in M. xenopi and
M. avium subsp. avium is in fact not a truly discordant result since
the strains were correctly identified with the species-specific
markers (strain 82, 85–86; Figure 3). The NTM 16S rRNA
marker was included to discriminate a range of NTM species from
the MTBC but is not able to detect all NTM species. The absence
of the marker is due to variation in the sequence targeted by the
MLPA probes within the different NTM species.
Comparison of MLPA results for drug resistance to other
molecular methods
A total of 13 MLPA probes (Table 1) for the detection of
molecular markers associated with resistance to first and second
line drugs were validated. Results were compared to data obtained
by reverse hybridisation assays or post-MLPA sequencing of the
targeted loci. Of the 1144 characteristics tested for drug resistance,
195 (17.0%) could be compared to previously obtained data
(Figure 3). At least one positive and one negative result validated
by another method was obtained for all 13 probes. Only one
discordant result was identified (characteristic embB-306 in strain
10) out of the 195 characteristics tested (0.5%) for which the
resistant genotype was known. This discrepancy was not due to the
threshold selected but was a result of a lack of specificity of the
embB-306 MLPA probe for one allele associated with resistance;
in strain 10, analysis by HAIN GenoType MTBDRsl and post-
MLPA sequencing revealed a methionine to isoleucine codon
change (ATG to ATA) in the embB-306 locus whereas the MLPA
produced a ‘‘wildtype’’ call. Previous MLPA analysis of embB306
mutant strains also demonstrated that the embB306 MLPA probe
is unable to detect this ATG to ATA codon change [28].
Reproducibility of the assay
For the analysis of the intra-assay and inter-assay reproducibil-
ity, four MTBC strains (strains 42, 75, 16 and 27) were analysed in
duplicate by MLPA in three independent experiments (Figure 5).
Intra-assay and inter-assay reproducibility were determined by
calculating mean MFI values, standard variations and coefficients
of variation. Two markers for drug resistance and four markers for
species identification were included in the analysis (Figure 5). For
all four MTBC strains the results (presence or absence of MLPA
products) and the values (MFI) were reproducible within one
experiment and between the three experiments. These results were
concordant with previously performed MLPA analysis of these
strains.
Discussion
In this study we have validated the bead-based MLPA and
thereby demonstrated the potential of MLPA to simultaneously (A)
identify a range of drug resistance markers (B) discriminate
between members of the M. tuberculosis complex (MTBC) and
detect specific genetic lineages (C) detect and identify the clinically
most relevant non-tuberculous mycobacterial (NTM) species M.
kansasii, M. xenopi, M. avium complex, M. avium subsp. avium, M.
fortuitum [42].
Several post-diagnosis methods are available, each providing
detailed information on a specific trait of the infecting strain(s)
[21,37,38,43,44]. However, for full characterization of MTBC
isolates multiple methods are currently needed. Therefore a single
multiplex method allowing simultaneous detection of a range of
characteristics, including species confirmation and internal quality
control would be beneficial. The rapid expansion of whole genome
sequence (WGS) databases allows the rational selection of robust
and informative genetic markers from a clonal organism such as
M. tuberculosis [25,26,33,34,45,46], which can then be directly
utilised by SNP detection methods with high multiplexing abilities
[31,47].
Previously we reported the development of an M. tuberculosis
specific molecular assay which allows the simultaneous detection of
18 discriminatory genetic markers providing information on drug
Bead-Based M. tuberculosis-Specific MLPA
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resistance and bacterial lineage [28]. This method is based on
Multiplex Ligation-dependent Probe Amplification (MLPA) [31]
where results are read by capillary electrophoresis. Here we have
expanded this MLPA assay and transferred the method to a bead-
based suspension array by replacing the traditional length-coded
system for the internal xTAG technology (Luminex Corp. USA),
which enables readout on a MAGPIX device (Luminex Corp.,
USA).
The MLPA assay described here includes 12 previously
described and validated markers [28] and 26 additional genotypic
markers allowing the delineation of clinical isolates into the six
main lineages of the MTBC [25,26,46] and the detection of
NTMs. It further contains markers to detect resistance to
streptomycin, fluoroquinolones, aminoglycosides and capreomy-
cin, in addition to previously described isoniazid and rifampicin
resistance markers [28]. These resistance markers are reported to
be responsible for 53 to 62% of fluoroquinolone resistance, 71 to
97% of amikacin, kanamycin and capreomycin or amikacin,
kanamycin resistance, and 22 to 64% of streptomycin resistance
[48–57].
To validate the assay, we assessed the performance of the
additional MLPA probes and transfer of the assay to the MAGPIX
system by screening a well-characterised panel of 88 strains with
either 23 or 43 markers, as the range of MLPA-probes was
extended during the development of the assay.
Initial experiments with the bead-based MLPA showed that
MFI values were sensitive to the relative concentration of the
labelled, unlabelled primers and dNTPs (data not shown) but by
limiting the concentration of the unlabelled primer, to one quarter
of that of the labelled primer, highly reproducible MFI values
could be obtained (Figure 5). Based on the MFI values obtained
for 13 MLPA characteristics from analysis of 24 mycobacteria
strains and two non-mycobacteria strains, we set a threshold value
of 150 MFI and for all measurements with an MFI over this value
we assumed an MLPA product was present. For species
identification of the analysed strains we used a decision tree
created on the basis of the most recent comprehensive MTBC
phylogeny ([25,26] and Figure 2). Assignment of strains to a
specific MTBC lineage and determination of drug resistance was
based on the presence or absence of specific markers (SNPs or
RDs). Classification of the strains was done by automated
interpretation of the MLPA results using a dedicated Excel sheet.
Targeting lineage-specific markers facilitates identification of
specific genotypic groups, but does not generate classical ‘‘typing
profiles’’. MLPA results can be screened for internal consistency as
each strain should only be positive for genotypic markers
associated with a single lineage and negative for all other markers
(Figure 2). The presence of markers from multiple lineages thus
results in an inconstant profile that will easily be recognised. Such
a profile would indicate either false positive or negative calls, a
mixed culture, or that the selected marker is in fact not lineage-
specific.
For three MLPA probes an additional central sequence-specific
spanning oligo was designed, thus to obtain a positive signal three
oligos must be ligated at two points. These oligos (targeting M.
xenopi, M. avium subsp. avium and M. fortuitum, Table 1) targeted the
Figure 5. Reproducibility of the MLPA assay. DNA from M. tuberculosis strains 16, 27, 42 and 75 was analysed by MLPA in duplicate and in three
experimental replicates. Mean Median Fluorescence Intensity (MFI) values with standard error of the mean (SEM) are shown. Each bar represents one
experiment. The dashed line at MFI 150 indicates the set threshold.
doi:10.1371/journal.pone.0043240.g005
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rRNA interspacer region of NTM species and the introduction of
a second ligation site ensured their specificity which could
otherwise not have been obtained with a traditional MLPA probe.
We screened 88 strains for in total 3059 characteristics. The vast
majority (3034/3059) of these characteristics were consistent with
previous molecular characterizations, of which 2037/3034 were
directly supported by other molecular methods and 997/3034
were consistent with but not directly supported by previous
molecular characterizations. Inconsistent results, that directly
conflicted or were inconsistent with previous molecular charac-
terization, were obtained for 25/3059 of the characteristics tested
(Figure 3).
The majority of the discrepant results (strains 43–46, 49–52, 54–
58, 60–61, 68–69, 71–72, 77) were due to the markers pks15/1–7,
acs-1551 and RD131. For these markers MFI values just above the
threshold (150 MFI) were obtained in many cases (Figure 4 and
Table S2), resulting in these markers being called present along
with other markers specific for different lineages in some strains.
Consequently these strains could not be assigned to a specific
MTBC (sub)lineage by MLPA (Figure 3).
Individual adjustment of the threshold values for the markers
pks15/1–7, acs-1551 and RD131 could have resolved this issue for
14 out of 20 strains with conflicting results; a single genotype,
consistent with other genotyping methods, could then be assigned
to these 14 strains. However, individually set thresholds would still
have not resulted in assignment to a single TB (sub)lineage for
strains 44, 54, 58, and 60–61, since no additional information of
genotype-specific markers was present in these strains that were
analysed with the initial probemix targeting only 23 markers. The
markers acs-1551 or RD131 alone or in combination are not
sufficient to assign a strain to the Beijing lineage. Strain 43 would
have been identified by MLPA as a LAM strain but spoligotyping
assigned this strain to the T family.
From this analysis we believe that automated calling of MLPA
results is feasible and that future versions of the MLPA would be
even more accurate if individually normalised thresholds are
introduced for each marker targeted (Figure 4). The ability of a
single threshold, as used here, to result in such consistent data is
nonetheless encouraging and demonstrates that the reproducibility
and overall signal-to-noise ratio between positive and negative
markers was adequate. Signal-to-noise ratios may still be improved
by further optimization of the probemix or the procedure; for
example by enhancement of the positive MFI signals through
exonuclease digestion of the non-labelled PCR-product [58–60].
As mentioned earlier, four markers were removed from the
selection of 47 markers initially included in the assay (Figure 4).
The 8 bp deletion in pncA was predicted to be specific for strains
of the ST41 spoligotype which are highly prevalent among MDR
strains in Bulgaria. The deletion was first reported in strains from
Quebec, Canada [61] and the ST41 spoligotype was discovered in
Turkey [62]. Retrospective comparative analysis suggested that
strains belonging to the ST41 spoligotype carried the characteristic
8 bp deletion in pncA. The MLPA probe designed for detection of
this deletion did not identify the two ST41 strains (strains 58 and
59, Table S1), since MFI values for the pncA probe were similar to
non-ST41 strains (Table S2 and Figure 4). Subsequently
sequencing confirmed this deletion was not present in these strains
(results not shown). This suggests that the Quebec strain and the
Bulgarian ST41 isolates have similar spoligotypes by convergence,
or alternatively that the pncA deletion is specific for a branch of
the ST41 strains.
Genotypic markers that allow the identification of the six main
MTBC lineages were included. This broad range of markers is
quite effective for the analysis of globally diverse collections of
strains. However, inclusion of characteristic markers for targeting
locally prevalent strains may be more informative. For instance, in
East Asian countries, where Beijing genotypes are the dominant
strains, increased discrimination within the Beijing lineage would
be more appropriate. The MLPA assay described here included a
panel of five markers that allowed further delineation of the
Beijing genotype (Beijing SA+, SA2, V+, V2, CHIN+, CHIN2
and K1 [33,34]).
The ability to simultaneously detect different mycobacterial
lineages and specific drug resistance would not only be useful for
mapping the prevalence and spread of (drug-resistant) TB in a
region, but also to track emerging and potentially more virulent
genotypes. For example, a significant proportion of the MDR-TB
cases in Europe are due to large clusters of a limited number of
epidemic strains. In fact, 84% per cent of the clustered MDR-TB
cases identified in Europe from 2003 to 2007 were caused by only
seven strains, all belonging to the Beijing genotype [63]. Strains
belonging to these clusters have been isolated and subjected to
detailed genetic analysis which has revealed distinctive markers
that identify and discriminate within the Beijing lineage
[33,34,64]. A selection of these has been included in our assay
(Table 1), among which RD131, a genomic region which is
deleted in one of the largest and most widespread European MDR
clusters, cluster E0054 [63]. The absence of a signal for RD131
along with the presence of two markers specific for larger
subgroups of the Beijing clade (mutT2-58 and fbpB-238) allowed
us to specifically identify members of the E0054 cluster (Table S2
and Figure 3; strains 1, 27 and 73).
We used Ag85C-103 to classify strains belonging to the LAM
lineage [65]. From the results obtained the MLPA probe targeting
this marker is functional and specific (Figure 3; strains 7, 46, 41,
52, 53). However, strain 43 was assigned to LAM by MLPA, but
assigned to the T lineage by spoligotyping. Gibson et al. [65]
encountered the same inconsistencies between Ag85C-103 and
spoligotyping. In their study, supplemental IS6110 RFLP analysis
showed that the Ag85C marker was more discriminatory for LAM
strains than spoligotyping. Our results also support the finding of
Abadia et al. [66] who studied two strains with a spoligotype
identical to strains 60 and 61 (TUR). Their strains were initially
identified as LAM7-TUR strains on the basis of a specific
spoligotype signature. However, using SNP typing, Abadia et al.
found their strains lacked the LAM-associated ligB SNP but
contained the T sublineage TUR-T3-Osaka-associated ligC SNP.
Thus, the spoligotype signature was renamed TUR as a result of
‘‘SNP-resolved spoligotyping’’. The absence of the LAM-associat-
ed Ag85C-103 marker in strain 60 and 61 in our study supports
the conclusion that these strains are not members of the LAM
genotype.
MLPA could not confirm the classification of strain 21 which
has an unusual genotype and was previously assigned to ‘‘non-
Beijing blue’’ by MLST and LSPs (strain 21 is referred to as K100
[25,26]). In addition, none of the standard signature patterns could
be obtained for this strain by spoligotyping [25].
The MLPA is a flexible assay with regard to the inclusion of
markers to be targeted; markers included in the probemix can be
easily exchanged with other validated markers by replacing the
target-specific sequence of individual MLPA-probes, but retaining
the xTAG sequence. For some lineages multiple genotypic
markers have been discovered [14,33,34,46,67], so alternative or
additional SNPs or LSPs associated with the lineage targeted could
be included.
Replacement of nonfunctional probes targeting specific resis-
tance mutations is more challenging than replacement of
genotypic markers, as the design of the probe is restricted to
Bead-Based M. tuberculosis-Specific MLPA
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target exactly these mutations; drug resistance mutations are not
equivalent to each other and the majority of drug resistance
mutations have a unique prevalence in a certain geographical
location. One possibility to resolve nonfunctional MLPA probes
for the detection of specific drug resistance mutations is to target
the wildtype locus instead. In the current assay we targeted the
wildtype sequence for the indirect detection of multiple mutations
in codon 306 of embB ([28] and Table 1). However, since MLPA
focuses on direct detection of targeted genetic markers, targeting
the wildtype sequence is most feasible if polymorphisms are
confined to a single nucleotide or codon as shown for the embB-
306 marker. Therefore targeting all possible mutations that are
clustered in a genomic region, such as mutations in rpoB, is more
difficult by the current MLPA procedure than for some other SNP
detection methods, such as molecular beacon or line probe assays
[37,38,44,68,69].
Three quality controls were included, giving information on
complete denaturation (LumD), sample DNA quantity (LumQ)
and efficient hybridisation of MLPA products to the beads
(LumH). All three internal controls are functional and can be
added directly to the DNA sample with the MLPA probemix.
Further detailed analysis of the controls will reveal the perfor-
mance conditions of the LumD and the detection limits of the
LumQ and LumH controls.
MLPA allows lineage or strain identification, but is not a typing
method and thus does not replace typing methods such as
spoligotyping, MIRU-VNTR, or whole genome sequencing.
Notably, high throughput methods for spoligotyping and ‘‘spoli-
goriftyping’’ have recently been developed which also utilise
Luminex technology [39,66,70,71] (Gomgnimbou et al, manu-
script in preparation), offering the potential to perform character-
ization as well as comprehensive typing using the same technology.
Although profiling techniques such as MIRU-VNTR and
spoligotyping in principle have a higher discrimination than
SNP detection methods, like MLPA, these techniques are more
prone to problems associated with homoplasy [72]. An example of
this is explained above with incongruent results obtained for
spoligotyping and the ligB and Ag85C SNPs and with MIRU-
VNTR [73]. In addition, SNP typing is platform-independent and
can therefore easily be compared between methods and labora-
tories and remains informative even if whole genome sequencing
becomes the standard method to characterise clinical strains.
Here we describe the validation of the bead-based MLPA to
characterize Mycobacterium tuberculosis isolates using 88 selected well-
characterised strains. We have demonstrated that MLPA is a
uniquely informative single test that allows the identification of
MTBC members from culture as well as the detection of mutations
associated with important phenotypes. Multiplex molecular
methods such as MLPA produce definitive, internally consistent
results and could provide real time information on an evolving
tuberculosis epidemic. This type of data could previously only be
obtained by detailed retrospective analysis of small collections of
strains [2]. The MLPA assay appears suitable for transfer to an
automated cartridge based system as it uses equipment that is
robust and calling the presence and absence of markers screened
was automated. The MLPA is currently being piloted in three
research laboratories. The sensitivity and specificity of the MLPA
assay will be evaluated in a diagnostic laboratory in a region with a
high burden of MDR-TB.
Supporting Information
Table S1 Table shows the drug resistance profiles and
species identification of all strains analysed in this study
as determined by various methods.
(XLSX)
Table S2 Table shows marker-specific MFI values
measured by the bead-based MLPA of 88 mycobacterial
and one non-mycobacterial species.
(XLSX)
Table S3 Summary table of Figure 3.
(XLSX)
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